SAN FRANCISCO, Nov. 11, 2015 (GLOBE NEWSWIRE) -- Invuity, Inc. (NASDAQ:IVTY), an advanced medical technology company, today announced that company management is scheduled to present at the following upcoming investor conferences:

• The Stifel Healthcare Conference on Wednesday, November 18, 2015 at 1:30 p.m. ET in New York City.
• The Canaccord Genuity Medical Technology & Diagnostics Forum on Thursday, November 19, 2015 at 11:30 a.m. ET in New York City.

Live, listen-only webcasts of the presentations may be accessed by visiting the Events & Presentations section of the Company's website at www.invuity.com under Investors & Media. A replay of the webcasts will be available shortly after the conclusion of the presentation and will be archived on the Company's website for 30 days following the presentation.

About Invuity®

Invuity, Inc. is a medical technology company focused on developing and marketing advanced photonics devices to improve the ability of surgeons to illuminate and visualize the surgical cavity during minimally invasive and minimal access open surgery. The company's patented Intelligent Photonics™ technology enables enhanced surgical precision, efficiency and safety by providing superior visualization. Clinical applications include breast and thyroid oncology, plastic reconstructive, spine, orthopedic, cardiothoracic and general surgery among others. Invuity is headquartered in San Francisco, CA. For more information, visit www.invuity.com.

CONTACT: Media:
         Miranda Duncan
         Waggener Edstrom
         415-342-9430
         media@invuity.com
         
         Investors:
         Matt Clawson
         Pure Communications
         949-370-8500
         irdept@invuity.com

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.